MNKPF - Mallinckrodt reports Q2 results

• Mallinckrodt press release ( NYSE: MNK ): Q2 net loss of $257.2M
• Revenue of $468.7M (-14.2% Y/Y).
• Bryan Reasons, EVP and Chief Financial Officer, said, "Having eliminated more than $1.3 billion in debt principal and closed a new $200 million accounts receivable financing facility with the overhang and expense of the opioid litigation now behind us, we have a clear path forward to continue operating the business in a responsible manner and delivering benefits to patients. Looking ahead, we are focused on further reducing debt as we continue enhancing operating efficiencies and generating additional cash through the successful execution of our strategic priorities."
• For FY2022, the company expects total net sales of $1,875M to $1,925M and Adjusted EBITDA of $630M to $660M.

For further details see: